Boehringer Ingelheim announced today new data from the pivotal Phase II Effisayil™ 1 trial, presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Boston. The Effisayil™ 1 trial, recently published in The New England Journal of Medicine, showed significant clearance of skin pustules in patients with generalized pustular psoriasis (GPP) flares within…
從這篇文章可以得到什麼：
- The Effisayil™ 1 trial, recently published in The New England Journal of Medicine, showed significant clearance of skin pustules in patients with generalized pustular psoriasis (GPP) flares within….
- 勃林格殷格翰今天公佈了關鍵 II 期 Effisayil™ 1 試驗的新數據，該試驗在波士頓舉行的 2022 年美國皮膚病學會 (AAD) 年會上公佈。
- 訂閱是免費的。
